ichroma™ COVID-19 Ab in conjunction with ichroma™ II Reader is an in vitro diagnostic fluorescence Immunoassay intended for qualitative detection and differentiation of IgG/IgM antibodies to the novel coronavirus SARS-CoV-2 in human venous whole blood, serum or plasma samples.

Overview

ichroma™ COVID-19 Ab test system is a rapid in vitro diagnostic test that qualitatively detects anti-SARS-CoV-2 IgG/IgM antibodies in venous whole blood, serum, or plasma samples with high sensitivity. The antibodies detected by the test indicate that a person had an immune response to SARS-CoV-2 irrespective of whether the individual developed any symptoms after the infection, or he/she was asymptomatic. The test results are important in detecting infections with few or no symptoms. In the case of COVID-19, time from exposure to onset of symptoms varies from two days to two weeks. IgM antibodies usually appear in the patient’s blood within a week after infection while IgG antibodies appear within 2-4 weeks after infection. Hence, the detection of anti-SARS-Cov-2 antibodies in patient specimens has clinical significance for prevention or effective control of community spread of COVID-19.